SCVC
South China Venture Capital is a private equity investment fund management firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed SCVC Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
South China Venture Capital is a private equity investment fund management as the main business of professional investment management organization. Under the jurisdiction of the three branch of the fund management company: Shenzhen South China Invsetment Management Co.Ltd, South China (Tianjin) Equity Investment Fund Management Co. Ltd., Shenzhen Zhongnan Hongyuan Invsetment Management Co. Ltd.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2022 | Accro Bioscience | Series B | 0 |
| 6/2019 | EpimAb Biotherapeutics | Series B | 74M |
| 6/2017 | TIAN JIAN | Angel Round | 442.7k |
| 8/2017 | Chongxin Chongwu | Series A | 454.9k |
| 6/2018 | Daily Shakes | Angel Round | 453k |
| 1/2023 | Huixin Bio | Seed Round | - |
| 3/2019 | Aluksen Technology | Series A | 10.7M |
| 4/2018 | HUAHUI TECHNOLOGY | Series C | 4.8M |
| 2/2021 | Drug Farm | Private Equity Round | 56M |
| 9/2013 | Shaanxi Xifeng Liquor Co,.LTD | Series A | 1.6M |
| 10/2019 | Ipoweru.cn | Series A | - |
| 12/2017 | Wuxian Zhitou | Series A | 1.5M |
| 4/2013 | sungoal | Angel Round | 483.7k |
| 11/2020 | Inmagene Biopharmaceuticals | Series B | 0 |
| 2/2021 | Cullgen | Series B | 0 |
| 1/2019 | Apollomics | Series B | 100M |
| 3/2021 | Innoforce Pharmaceuticals | Series A | 96M |
| 12/2021 | Innoforce Pharmaceuticals | Series A | 0 |
| 6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
| 10/2020 | Zhuishi Technology | Seed Round | - |
| 3/2022 | Wuxi Xinxiang | Series A | 15.8M |
| 1/2015 | Biyao | Series A | 1.6M |
| 11/2017 | LEADRIVE | Angel Round | 151.2k |
| 5/2022 | Liufang Technology | Series A | - |
| 11/2020 | CARsgen Therapeutics | Series C | 0 |
| 5/2022 | Immunowake | Series A | 20M |
| 3/2020 | GenFleet Therapeutics | Series B | 57.7M |
| 11/2022 | Zheta Technology | Series A | 12.6M |
| 5/2022 | Liufang Technology | Series A | - |
| 5/2022 | Immunowake | Series A | 0 |
| 3/2022 | Wuxi Xinxiang | Series A | 0 |
| 1/2022 | Accro Bioscience | Series B | 0 |
| 12/2021 | Innoforce Pharmaceuticals | Series A | 0 |
| 6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
| 3/2021 | Innoforce Pharmaceuticals | Series A | 0 |
| 2/2021 | Cullgen | Series B | 0 |
| 2/2021 | Drug Farm | Series A | 0 |
| 11/2020 | Inmagene Biopharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
